News
Super Micro Computer, Inc.'s Q3 miss is a buying opportunity amid AI growth. Click for why it’s mainly a temporary setback ...
In 2024, the European Medicines Agency (EMA) approved lecanemab for the treatment of early Alzheimer's disease in patients without contraindications or risk factors for side-effects. This approval ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback